	2023 EFPIA DISCLOSURE (Inc. Vaxcines Europe)										
	Date of publication: 28th of June 2024										
	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL		Contribution to costs of Events			Fee for service and o	
						Donations and Grants to HCOs and POs	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees excl. VAT	
	MONIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. temization should be evalidate for the individual Recipient or public authorities' consultation only, as										
	Morten Brændengen	Oslo	Norway	diakonhjemmet, Oslo	ı	N/A	N/A			10,000	
	Svein Dueland	Oslo	Norway	Kreftkliniken		N/A	N/A			7200	
	Inger Marie Løes	Bergen	Norway	Bergen hospital		N/A	N/A			7200	
	Eva Hofsli	Trondheim	Norway	Kreftkliniken		N/A	N/A			7200	
	Arne Westergaard	Oslo	Norway	Afdeling Kreftbehandling		N/A	N/A			7200	
æ				-		N/A	N/A				
HCPs						N/A	N/A				
	OTHER, NOT INCLUSED ABOVE - where information cannot be diclased on an individual basis for legal reasons										
	Aggregate amount attributable to transfers of value to such Recipients N/A N/A N/A										
	Number of Recipients in aggregate disclosure					N/A	N/A				
	N of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed						N/A				
	MONOGUE MANTO DECIDIES - use free per MCD. Let all transferred placed strong a per all for an included MCD well be considered per the midulated Acceptants a public confinences: consultation only, as										
	Norsk Gastrointestinal Cancer Gruppe	35.000 NOK									
	Nordic AML Group 2023	Grant to support the meeting the 24-25th of August 2023									
×	Onkologisk Forum Norge	Grant to support the meeting the 16-17th of November 2023									
HCOs								1			
	OTHER, NOT INCLUDED ABOVE - where information cannot be diclased on an individual basis for legal reasons										
	Aggregate amount attributable to transfers of value to such Recipients N/A N/A										
	Number of Recipients in aggregate disclosure						N/A				
	% of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed						N/A				
	MOVIOUM, MAMED DSCIDURET - one law pay PO (i.e. all strangers of value during a year for an individual PO will be jumined up transversion should be enabled for the individual Respirator public authorizer' (consultation only, as appropriate)										
õ	GTHER, NOT ACCUSED ARBOVE - where informations cannot be defined on an individual basis for long reseases. Appropria amount attributables to treatfers of value to such Recipions. NA. NA.										
_	Aggregate amount attributable to transfers or value to such recipients Number of Recipients in aggregate disclosure						N/A				
							N/A N/A				
	N of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed						NyA				
		AGGREGATE DISCLOSURE Transfers of Value to Research & Development as defined									

onsultancy	
Related expenses agreed in the fee for service or	
consultancy contract,	
including travel &	
accommodation	
	T .
	4
	1
	1
	1
	1
I	
I	
I	
	1
-	
	N/A